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Abstract
Background: Cancer survivors rate fertility as one of the most important determinants of their quality of life in the
years after cancer treatment. We seek to describe the reproductive goals of women affected by gynecologic
cancers and investigate their specific challenges during fertility preservation (FP) counseling.
Methods: Univariate & multivariate logistic regression were used for quantitative analysis of objective FP counseling
measures between women with gynecologic (GYN) and non-gynecologic (non-GYN) cancers from a cross sectional
survey. Framework analysis was conducted on patient perception of physician-patient interactions.
Results: Of the 2537 women contacted, 1892 responded and 1686 reported treatment with potential to impact fertility.
Among women with GYN cancers 52% wanted future children. Women <35 years were interested in FP (74%). Women
with Gyn cancers received less FP counseling than women with non Gyn cancer (OR 0.5 95% CI 0.4–0.6). Three hundred
twenty-four patients gave qualitative answers. Patient identified barriers included incomplete FP information
(59%), nondisclosure (29%), a disinterest in FP (5%), and a perceived urgency to start treatment (7%).
Conclusions: Women with gynecologic cancers are less likely to be counseled about FP in comparison to
women not affected by gynecologic cancers despite having similar fertility goals. We have identified patient
perceived barriers to optimal FP counseling which may be improved upon to increase the value of FP and
optimize quality of life for cancer survivors of gynecologic malignancies.
Keywords: Fertility preservation, Gynecologic cancer, Cancer survivorship, Counseling
Background
Comprehensive cancer care has made a transition to
“quality survival” versus survival alone [1, 2]. Women
affected by cancer in their reproductive years are in a par-
ticularly vulnerable position, having to balance their treat-
ment plan and the possibility of diminished reproductive
potential as cancer survivors [3]. The incidence of all can-
cers affecting women less than 50 years old has continued
to rise. In 2011, women with gynecologic cancers
accounted for 13% of the total incidence of women with
cancers below the age of 50. Meanwhile, improvements in
cancer screening and treatment modalities have led to in-
creased cancer survival. Young women are living longer
after their cancer treatment and thus the importance of
quality of life during the years following is tantamount to
the initial success of treatment itself [4, 5].
Cancer survivors rate fertility as one of the most
important determinants of their quality of life in the
years after treatment [6]. Among young cancer survivors
who have never had children, 75% desire building a
family [7]. Meanwhile, women who have lost their fertility
as a result of their gynecologic cancers demonstrate
depression, grief, stress and sexual dysfunction. While
adoption or third party reproduction using donated
gametes is an option, most patients express a desire to
have their own biological children [8, 9]. It has been
demonstrated that women may change their treatment
decisions based on infertility concerns alone [10].
However, women affected by cancers are not consistently
counseled about the risks of treatment to future fertility
and/or referred to a FP expert [11–13].
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Given the context and the conditions under which FP
takes place, the patient, the providers and the medical
system face numerous practical obstacles and psycho-
logical difficulties at the time of FP counseling. Previously-
described barriers to FP include: suboptimal counseling,
insufficient office time by the primary caregiver, a percep-
tion of patient disinterest, financial costs and insurance
barriers, an urgency to initiate treatment, and a deficit in
the primary provider’s knowledge base regarding FP
[13, 14]. Interestingly, cost has not been shown to
be the unique or overwhelming factor dissuading
women from undergoing FP [15]. However, previous
studies demonstrate important information deficits:
more than 50% of physicians caring for women with
cancer state that they rarely refer patients to a reproductive
endocrinologist and only 38% of oncologists stated that
they provided their patients with written information about
FP [6, 16]. These layers of obstacles have led to FP
utilization as low as 4% among reproductive aged women.
Meanwhile, more recent studies demonstrate that among
women receiving a FP referral approximately two-thirds
opted for a FP treatment [17].
We set out to describe the reproductive health and FP
counseling among women affected by gynecologic
cancers. Our study seeks to describe the reproductive
goals of women affected by gynecologic malignancies
in addition to delineating the challenges confronted by
women with gynecologic cancers in receiving optimal
FP counseling. In uncovering their challenges, we offer
specific counseling mechanisms in order to improve
the quantity and quality of FP counseling and ultim-
ately cancer survivors’ quality of life.
Methods
We performed a retrospective survey study, using the
California Cancer Registry (CCR) to sample women
across the state of California. All study procedures were
reviewed and approved by the IRB committee at the
University of California, San Francisco Committee on
Human Research.
Study population
Women with gynecologic malignancies were contacted be-
tween December 2010 and February 2013. The detailed
methods of the retrospective survey have previously been
published and are available for reference [6, 18–20]. In brief
summary, reproductive-age women from the California
Cancer Registry (CCR) were sampled if they had a history
of gynecologic cancer (cervical, ovarian, uterine/endomet-
rial, vaginal/vulvar, and placental). This group was com-
pared in this study to a control group within the CCR that
consisted of reproductive age women (18-40 years) with
leukemia, Hodgkin’s Disease, Non-Hodgkin Lymphoma,
breast cancer and gastrointestinal cancers. These groups of
cancers were chosen for this study because they are com-
mon gynecologic and non-gynecologic malignancies that
may be treated with fertility-compromising surgery, chemo-
therapy, or radiation. Inclusion criteria included limitations
on age (18 to 40 years of age at diagnosis) and time of diag-
nosis (1993 to 2007). The CCR updates its researchable
database every three years, 2007 being the most recent at
the time of initiation of this study. All available cases in the
time period were selected for potential participation.
Survey
A questionnaire was developed to query reproductive his-
tory before and after cancer treatment. The methodology
regarding development and validity-assessment can be ref-
erenced in previously published work by our group [20].
The survey included information regarding FP counseling,
patient described interest in future childbearing and back-
ground information regarding patient’s obstetric history.
In the survey targeted at women with gynecologic cancers
a separate free hand section was provided for the response
to the question, “What did your doctor tell you about
how cancer treatment could affect your ability to have
children?”
Data analysis
Survey data were merged with CCR data using a unique,
anonymous identifier code. Statistically significant results
were defined as p < 0.05 for a two sided P value. The
Student’s t-test was utilized to compare responders versus
non-responders. Multivariate regression analysis was con-
ducted to determine the odds of FP counseling between
groups. Statistical analyses were performed using STATA
Version 11 (College Station, TX). Differences in diagnoses
and demographic characteristics between women who did
and did not respond were examined using CCR data.
A framework analysis was then carried out on all the
qualitative responses to the free text response, “What
did your doctor tell you about how cancer treatment
could affect your ability to have children?” Two indi-
viduals reviewed the responses to categorize each
response. A third individual was asked to review the
response if non-concordant decisions were made by
the first two. Patients were included in more than one
category if they distinctly expressed barriers involving
2 or more categories. The methodology for a frame-
work analysis was adhered to per established guide-
lines [21].
Results
Among reproductive age women (18–40 years) in the
CCR between 1993 and 2007, we contacted 2537 women
and 1892 responded to the survey. The non-responders
stated that the most common reasons for declining to
complete the survey was the emotional difficulty, the
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length of the survey and a current disinterest in child-
bearing (Fig. 1). Among the 1892 responders, we identi-
fied 1686 (89%) as women who may have had their
fertility impacted by their treatment and 768 of these
had known gynecologic cancers. A total of 324 gyneco-
logic cancer survivors who had treatment with potential
to affect fertility articulated a written response to the
question, “What did your doctor tell you about how can-
cer treatment could affect your ability to have children?”
Shown in Table 1 are the comparisons of the 1892
responders and 645 who declined participation, based
on disease and demographic data in the CCR. There
were small, but statistically significant differences be-
tween responders and non-responders in terms of age,
time since diagnosis, age at treatment, socioeconomic
status (calculated from median income and education
for the census block group of residence at diagnosis) and
stage of disease, as indicated by a SEER summary stage
index (range of 0-in situ) to 7- metastatic). The age and
childbearing desires of gynecologic and non-gynecologic
cancer survivors who completed our survey are listed in
Tables 2 and 3, respectively. Vulvar, vaginal, and pla-
cental cancer survivors were few in number (<15 total
respondents each). Given their small sample sizes,
these 3 cancer groups were excluded from further analysis.
Ovarian cancer survivors tended to be the youngest, most
likely to desire children, and most likely to conceive after
treatment. Overall, few women attempted pregnancy (3–
25%) despite a relatively high percentage of women who
desired children after treatment (31–58%).
Among those with gynecologic cancers and treatment
with potential to affect fertility 52% explicitly stated an
interest in future childbearing. Among women 18–35
years of age, 66% desired future children at the time of
their diagnosis and 74% of those expressed an interest in
FP. In the cohort of women older than 35, 35% still
wanted future childbearing with 49% of those expressing
an interest in FP. Nulliparous women of all ages were
more likely to desire children (OR: 2.0 95% CI 1.4–2.7).
These findings strongly support the presumption that
women with gynecologic malignancies especially young
women are interested in future childbearing and FP at
the time of their diagnosis.
Among women desiring future childbearing, 51% of
them were counseled regarding FP. The study group was
then compared to a group of cancer survivors comprised
from the California Cancer Registry who were affected
by non-gynecologic cancers (Leukemia, Hodgkin’s, non-
Hodgkin’s lymphoma, Breast or GI cancer). In compari-
son to women without gynecologic cancers, women with
gynecologic cancers received significantly less counseling
regarding FP (OR 0.5: 95%CI 0.4–0.6). Furthermore, this
trend remained consistent among the groups of women
most likely to desire future childbearing. Nulliparous
women with gynecologic cancers were counseled at a
lower rate than nulliparous women affected by non-
gynecologic cancers (57% vs 50%: OR: 0.6 95% CI 0.4–
0.86). They were also less likely to see a fertility specialist
(4% vs 8% 95% CI 0.2–0.9). Women less than 35 years of
age were less counseled if they had a gynecologic cancer
than if they had another type of cancer (54% vs 67%: OR
0.5: 95% CI 0.4–0.7) and also less likely to see a fertility
specialist (3% vs 8%, OR: 0.4 95% CI 0.2–0.8). Women
with an explicit desire for future childbearing followed a
similar pattern with regards to their FP counseling (51%
vs 67%, OR: 0.5 95% CI 0.4–0.7). Rates of consultation
with a reproductive specialist were similar in these
groups (7%, OR: 0.98 95% CI 0.6–1.6). Given the low
rates of FP counseling a further qualitative analysis was
conducted to investigate possible explanations for the
decreased counseling rates reported by cancer survivors
of gynecologic cancers.
A content and framework analysis done on 324
women’s qualitative answers identified six major themes
Fig. 1 Patient recruitment
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that emerged as significant barriers to adequate coun-
seling. The majority of women (59%) noted physician
truncation of information at the time of proposed treat-
ment to be a barrier to further FP counseling. Namely,
physicians were perceived to propose a treatment plan
followed by a statement such as, “This will mean you
won’t be able to have more children.” Patients expressed
an understanding that the treatment will affect their
fertility but were unaware of options for FP. Complete
omission of information regarding fertility or FP was
noted in 29% of poor FP counseling encounters. Incor-
rect knowledge based on the patient’s understanding
was relatively less common (8%). A perceived urgency to
start treatment was mentioned in 7% of responses, 6% of
patients expressed a fear of introducing the conversa-
tion with their provider while a negative physician atti-
tude or disinterest in FP accounted for 5%. Among all
patients completing the qualitative response section
11% expressed a positive counseling experience.
Women who had gynecologic or non-gynecologic
cancers identified the same primary sources for their FP
counseling. Notably, the primary sources of information
were the extended health care team (nursing, psych-
ologist, etc.) followed by either the surgeon or medical
oncologist. Women more likely to desire children and
consider FP identified their partner (OR 2.2, 95% CI
1.03–4.7), family members (OR 2.2, 95% CI 1.0–5.2)
or the internet (OR 4.8, 95% CI 1.4–16.8) as strong
influences in their decision-making.
Discussion
FP continues to be an underutilized asset in attaining
the survivorship goals of reproductive aged women
affected by cancer. It is well established that women
who become infertile after cancer treatment experi-
ence regret and decreased quality of life [6, 10, 18].
Meanwhile, it has been demonstrated that women who
merely undergo FP counseling have a decrease in
regret and an increase in quality of life following their
treatment [6]. Women place great importance on
future childbearing even when confronted with the
psychologically and physically jarring experience of a
gynecologic malignancy. In our study population more
than half of all the women with a gynecologic malig-
nancy were interested in future childbearing. The
inherent nature of a malignancy which directly affects a
woman’s reproductive organs is also unique in its im-
mediate effect on reproductive capacity and a woman’s
perception of herself [22]. This constellation of short
and long term ramifications necessitates a healthcare
system in which optimal FP counseling is available for
patients. In 2006, ASCO published guidelines strongly
advocating for FP counseling for all patients of repro-
ductive age [23, 24].
Table 1 Comparison of survey responders vs. declined
Completed survey (n = 1892) Declined (n = 645) p†
Age at diagnosis, years 32 · 4 (6 · 3) 34 · 4 (5 · 4) <0 · 01
Age at survey, years 43 · 3 (7 · 9) 45 · 3 (6 · 9) <0.01
Summary stage indexa 3 · 3 (1 · 4) 2 · 8 (1 · 5) <0 · 01
Socioeconomic Indexb 2 · 5 (1 · 2) 3 · 0 (1 · 4) <0 · 01
Time since diagnosis, years 10 · 8 (4 · 3) 10 · 7 (4 · 4) 0.63
†p-value from t-test comparing responders and non-responders
aSummary stage index = Surveillance Epidemiology and End Results staging index. Scores range from 0 (in situ) to 7 (metastatic)
bSocioeconomic index calculated from income, employment and education ranging from lowest to highest














Age at diagnosis, years, mean (SD) 33 · 4 (5 · 5) 33 · 3 (5) 31 · 7 (6 · 3) 36 · 1 (4 · 1) 37 · 9 (2 · 2) 33 (0)
Age at survey, years, mean (SD) 45 (6 · 9) 45 · 1 (6 · 5) 43 · 2 (7 · 7) 40 · 5 (7 · 1) 46 · 3 (4 · 4) 44 (0)
Years since diagnosis, mean (SD) 11 · 6 (4 · 2) 11 · 8 (4) 11 · 5 (4 · 3) 11 · 4 (4 · 5) 10 (3 · 1) 11 (0)
Children before treatment, % 65 73 55 64 77 100
Desiring children after treatment, % 52 49 58 51 31 0
Attempted pregnancy, % 13 10 25 3 17 0
Had children after treatment, % 8 7 15 1 8 0
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Despite various options for FP which offer an improved
and expedited FP process, a host of barriers appear to
remain in place leaving many women childless after
cancer therapy [14, 25]. In this study, we set out to
describe the reproductive goals of women affected by
gynecologic malignancies and the specific counseling they
receive in comparison to a control group of women with
non-gynecologic malignancies. The last phase of the pro-
ject evaluated the perceived barriers to receiving FP coun-
seling per the patients. While some women affected by
gynecologic cancers receive excellent FP counseling, the
general trends evidenced by this research unfortunately
demonstrate lower rates of FP counseling and decreased
access to a fertility specialist in comparison with women
not affected by a gynecologic cancer.
Our study demonstrates that women with gynecologic
cancers have similar reproductive goals in comparison to
women affected by other cancers. This is especially true
of women younger than 35 years. Among women who
represent those who would be most likely to desire
future childbearing (age <35 or nulliparous) women
were counseled at a significantly lower rate than those
without gynecologic cancers. Furthermore, these women
were less likely to consult with a fertility specialist. This
study also sheds light on the group of women >35 years
of age of which 49% stated that they would have been
interested in FP at the time of their diagnosis.
These findings are somewhat at odds with the dialogue
by the health care providers who care for women with
gynecologic cancers [16]. Gynecologic oncologists stated
that due to an Obstetrics and Gynecology training and
an interdepartmental familiarity they were more likely to
offer FP counseling [26]. Another recent study demon-
strates that Gynecologic Oncologists are more confident
in their knowledge of FP and thus they are more likely
to discuss this with their patients [27].
Patients were very insightful as to the specific areas in
which they found the counseling to be suboptimal. Most
notably, patients felt that information was truncated leaving
no room for further details or questions regarding FP. This
may be explained by a low physician confidence discussing
FP. A previous study demonstrated that only about half of
surveyed oncologists had moderate or high confidence in
their knowledge of FP options. Moreover, about 40% of
oncologists do not feel that their responsibilities include FP
counseling [27]. Complete omission of information was also
common. Possibly as a result of these communication
barriers regarding FP counseling, patients looked elsewhere
for FP information. The extended healthcare team and the
internet were the most common sources of additional FP
information patients sited. In contrast, a previous study
demonstrates that only 18% of oncologists gave their
patients any resources regarding FP [27]. We suggest
directing patients to preselected and reputable FP resource
websites and to print out patient information sheets.
The evolution of FP and the increasing number of
options for patients is accompanied with an increased
complexity in counseling patients prior to treatment for
gynecologic malignancies. ASCO has expanded the
scope of providers it recommends to offer FP counseling.
Specifically, the term “oncologists” was changed to
“health care providers” from 2006 to 2013 [23, 24]. The
findings in our study along with previous studies indi-
cate that the scope of knowledge and time required for a
complete discussion regarding FP counseling may be
unrealistic within the context of addressing the primary
oncologic needs. Our survey demonstrates a very low
proportion of patients (11%) endorsing a positive coun-
seling experience.
As this study’s participant population may have had
cancer and treatment prior to the current availability of
FP options, a time lag bias may have led to results which
overstate the current lack of FP counseling. However,
sustained low rates of FP referrals would argue that FP
counseling remains suboptimal. Moreover, we would not
anticipate a major change in the outcomes between our
groups of interest based on a time lag bias. As with any
retrospective survey study, the potential for recall bias is
present. However, we do not anticipate that the recall
bias would be significantly different between our groups
of interest in this study. The use of the California Cancer
Registry with a relatively high response rate allows this
study to have a high degree of generalizability. This study
also incorporates both a quantitative and qualitative














Age at diagnosis, years, mean (SD) 31.5 (6.7) 28.3 (7.2) 27.9 (6.2) 31.6 (6.0) 36.3 (4.0) 34.9 (4.6)
Age at survey, years, mean (SD) 40.9 (8.4) 37.0 (8.3) 36.5 (8.0) 40.5 (7.1) 47.1 (5.9) 44.6 (6.2)
Years since diagnosis, mean (SD) 9.6 (4.4) 8.7 (4.3) 8.6 (4.4) 8.9 (3.9) 10.8 (4.5) 9.7 (4.0)
Children before treatment, (%) 476 (52%) 46 (38%) 105 (37%) 88 (52%) 163 (73%) 76 (70%)
Desiring children after treatment, (%) 504 (54%) 71 (59%) 181 (63%) 82 (49%) 104 (47%) 61 (56%)
aData missing from 11 patients with Hodgkin’s disease or non-Hodgkin lymphoma
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element among the same group of patients to describe the
specific differences among women affected by gynecologic
cancers while also investigating the underlying reasons for
variance between women affected by gynecologic cancers
and those affected by other cancers.
Moreover, we identified specific barriers to counseling
which may be resolved with improved health care team
utilization, education and specific communication mech-
anisms. Physician truncation and omission of informa-
tion are most likely due to insufficient clinic time and
suboptimal physician confidence in their knowledge base
[27, 28]. It would be beneficial to incorporate other
members of the healthcare team who would be specific-
ally instructed in basic FP counseling. Ongoing CME
courses and intra institutional collaboration between
oncology and reproductive endocrinology will further
increase the dissemination of FP options. Communica-
tion regarding fertility impact and FP should end with
an open ended question in order to decrease perceived
truncation, omission and disinterest as these are the
primary concerns of patients. Finally, an established
system must ensure that patients undergoing cancer
treatment receive an expedited referral and appointment
with a reproductive endocrinologist should they choose
to explore further options.
This study describes the fertility goals of survivors of
gynecologic cancers and highlights findings which
demonstrate suboptimal counseling among this popu-
lation. We identify particular aspects of the physician-
patient communication which may be improved from
a communication and systems perspective. Additional
avenues in which patients seek out information regarding
FP are clearly highlighted based on our results. Utilizing
improved communication mechanisms to open up the
dialogue surrounding FP at first contact while increasing
the counseling and referral rate to FP specialists will offer
patients a spectrum of mental and reproductive health
benefits in their life as cancer survivors.
Conclusions
Women with gynecologic cancers are less likely to be
counseled about FP in comparison to women not
affected by gynecologic cancers despite having similar
fertility goals. We have identified patient reported
barriers which may be improved upon by increasing the
utilization of other members of the healthcare team,
increasing FP education and improving communication
to increase the value of FP counseling at the time of
cancer diagnosis. Ultimately, we must decrease barriers
and improve FP counseling for women undergoing treat-
ment of their gynecologic malignancy in order to fully
address their reproductive goals and optimize their
quality of life as cancer survivors.
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